New drug trial targets debilitating itching in rare liver disease
NCT ID NCT05543174
Summary
This study tested whether the drug TAK-625 could help people with Alagille Syndrome, a rare genetic disorder that causes severe liver problems and intense itching. Seven Japanese participants, including infants and children, received the drug for up to 34 months to see if it safely lowered harmful bile acids in their blood and reduced their itching. The goal was to find the right dose to better manage this lifelong condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALAGILLE SYNDROME (ALGS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Juntendo University Hospital
Bunkyo-ku, Tokyo, Japan
-
Kindai University Nara Hospital
Ikoma, Nara, Japan
-
Kyoto University Hospital
Kyoto, Japan
-
Miyagi Children's Hospital
Sendai, Miyagi, Japan
-
Osaka University Hospital
Suita, Osaka, Japan
-
Saitama Prefectural Children's Medical Center
Saitama, Japan
-
University of Tsukuba Hospital
Tsukuba, Ibaraki, Japan
-
Yokohamashi Tobu Hospital
Yokohama, Kanagawa, Japan
Conditions
Explore the condition pages connected to this study.